Another weight-loss jab will hit pharmacy shelves in Ireland at the end of next month – but it will only be available on ...

The first clinical trial of its kind found the weekly semaglutide jab cuts the amount people drink in one day by 40 per cent ...

This was significantly higher than the reduction achieved with standard dose Wegovy, 2.4mg, and the placebo, which resulted in losses of 17.5% and 2.4%, respectively. In addition, 33.2% of ...

Novo Nordisk's CagriSema trial raised concerns as patients reported weight loss but significant side effects. Investors ...

Citing topline data from its STEP-UP Phase 3b study, the Danish drugmaker said that while patients on regular Wegovy at 2.4 mg achieved 17.5% weight loss over the period, those on placebo ...

versus 16.7% of patients on semaglutide 2.4 mg and 0% of patients on placebo who hit that magnitude of success. Wegovy and Zepbound tipped to fuel $20B boom in heart failure market Overall ...

A high dose of Novo Nordisk’s obesity drug Wegovy led patients to lose substantial ... loss among people taking the currently approved 2.4-mg dose, and 3.9% among people taking placebo, Novo ...

Opens in a new tab or window Patients treated with semaglutide 7.2 mg achieved a 20.7% weight loss after 72 weeks compared with a reduction of 17.5% with semaglutide 2.4 mg (Wegovy) and 2.4% with ...

Semaglutide 2.4 mg is marketed under the brand name Wegovy. STEP UP is a 72-week efficacy and safety trial investigating subcutaneous semaglutide 7.2 mg compared to semaglutide 2.4 mg and placebo ...

Semaglutide, marketed under brand names such as Wegovy and Ozempic, already holds approvals for ... of 20.7% after 72 weeks compared to a reduction of 17.5% with semaglutide 2.4mg and 2.4% with ...